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Exploring the Impact of Changes in HIV-1 Viral Load
Due to Coinfections
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Abstract: High HIV-1 plasma viral loads (PVLs) in sub-Saharan
Africa, partly because of high rates of coinfection, may have been one
of the drivers of the “explosive” epidemics seen in that region. Using
a previously published framework of infectiousness and survival, we
estimate the excess onward HIV-1 transmission events (secondary
infections) resulting from coinfection-induced changes in PVL during
asymptomatic HIV-1 infection. For every 100 HIV-infected people,
each suffering 1 episode of tuberculosis infection, there are 4.9 (2.7th–
97.5th percentile: 0.2–21.5) excess onward HIV-1 transmission events
attributable to this coinfection. Other estimates are malaria 0.4 (0.0–
2.0), soil-transmitted helminths 3.1 (0.1–14.9), schistosomiasis 8.5
(0.2–38.6), ﬁlariasis 13.3 (0.3–89.2), syphilis 0.1 (0.0–1.6), herpes
simplex virus 4.0 (0.0–24.2), and gonorrhea 2.1 (0.1–8.0) trans-
missions. If these higher PVLs confer a shorter life expectancy and
higher infectiousness, then their impact on transmission is, in general,
reduced. For most HIV-1 coinfections, the duration of a single
infection is too short and/or the associated PVL elevation is too
modest to contribute substantially to onward HIV-1 transmission.
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INTRODUCTION
It has recently been suggested that high HIV-1 plasma
viral loads (PVLs) in sub-Saharan Africa, partly as a con-
sequence of high rates of coinfection, may have driven the
“explosive” epidemics in that region.1 PVL is positively
associated with heterosexual transmission,2,3 and systematic
reviews have highlighted the increases in PVL that occur in
the presence of various coinfections [tuberculosis (TB),
malaria, schistosomiasis, other soil-transmitted helminth
(STH) infections, ﬁlariasis, syphilis, herpes simplex virus
(HSV), and gonorrhea] and/or the decreases in PVL when
such coinfections are treated.4,5 It has therefore been
proposed that treatment and/or prevention of these coin-
fections could reduce PVL and hence reduce HIV-1 trans-
mission, in addition to the beneﬁts of reducing the burden of
these infections.6
We have previously demonstrated that the small reductions
in HIV-1 PVL observed in several randomized control trials of
HSV treatment of HSV/HIV-1–coinfected individuals7,8 do not
necessarily translate into substantial reductions in HIV-1 trans-
mission.7 Indeed, depending on the distribution of PVLs within
the population, small reductions in HIV-1 PVL may actually
increase the total number of onward HIV-1 transmission events.
This range of population-level outcomes is because of the
spectrum of PVLs in a population, in response to treatment and
the impact of PVL on survival and infectiousness. In general,
individuals with high PVL are very infectious but have a relatively
fast rate of CD4 decline and therefore a shorter HIV-1
asymptomatic period, whereas those with low PVL are less
infectiousness but with a longer asymptomatic period, resulting in
a longer window of opportunity for onward HIV-1 transmission.9
Recent trials have shown that treating HSV/HIV-1
coinfection with acyclovir and valacyclovir reduces HIV-1
PVL, which may reduce infectiousness,2,3 and has now also
been shown to decrease HIV-1 disease progression by decreas-
ing the rate of CD4 cell count decline during asymptomatic
HIV-1 infection.10–12 This delays the point at which antiretro-
viral therapy (ART) should be initiated but also provides more
opportunities for onward HIV-1 spread. The impact of
acyclovir/valacyclovir treatment on CD4 decline may be
because of it reducing HIV-1 PVL but may also be because
of its antiretroviral action reducing HIV-1 replication.13 How-
ever, because PVL is a major predictor of survival,14 it is
plausible that reducing elevated PVLs because of other
coinfections may have similar, if yet unquantiﬁed, effects.
Here, we apply our previously published framework7,9
for the impact of changes in PVL on infectiousness and
survival to estimate the public health impact of treating or
preventing HIV-1 coinfections, and more generally, the
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impact of interventions such as treatments or vaccines, which
reduce HIV-1 PVL to a nonnegligible level to identify at what
point such a reduction produces indisputable beneﬁts, without
potential deleterious effects on onward HIV-1 transmission.
We explore 2 scenarios: (1) the increase in PVL on acquiring
a coinfection increases infectiousness during the period of
coinfection and (2) this PVL increase additionally reduces
individuals’ projected durations of asymptomatic HIV-1
infection (by increasing the rate of CD4 decline).
METHODS
During the asymptomatic period of HIV-1 infection, the
transmission potential of an infected individual is deﬁned as
the mean number of persons that 1 index case can infect over
their whole asymptomatic period (the product of infectiousness
and duration of asymptomatic infection).9 It is a function of
set-point PVL (the PVL steady state reached after the peak
PVL in early infection and before progression to AIDS). The
concepts we explore are described by Baggaley et al7 and
detailed in Figure 1 and the Supplemental Digital Content
(http://links.lww.com/QAI/A619). Coinfection is assumed to
increase HIV-1 PVL when acquired transiently during asymp-
tomatic infection. We do not look at interactions between HIV-
1 and coinfections during acute- or late-stage infection because
these are periods where infectiousness changes rapidly and, in
the case of acute infection, infectiousness may be far higher
than would be predicted on the basis of PVL alone.15
We assessed the impact of coinfections on HIV-1
transmission by modeling a hypothetical population of 10,000
individuals with varying baseline PVLs in a generalized HIV-1
epidemic in sub-Saharan Africa in the absence of ART. We
used a frequency distribution of PVLs from a cross-sectional
survey of young men in Orange Farm County, South Africa.16
We simulated varying shifts in PVL due to coinfections.
Estimated elevations in PVL for each coinfection were sampled
from distributions taken from published literature4,5,17 as listed
in Figure 2 (for details of sampling, see Supplemental Digital
Content, http://links.lww.com/QAI/A619). Durations of each
coinfection were also taken from the literature (Fig. 2) and
sampled from a uniform distribution of 650% of the central
value. All individuals in the model population experience an
episode of coinfection, that is, results are not dependent on
prevalence levels of each coinfection, and thus results do not
represent any speciﬁc geographical area.
We looked at scenarios where the coinfection was
acquired at the start and halfway through the asymptomatic
period to explore the maximum impact of coinfection pre-
vention, especially relevant for long duration infections such
as HSV. We also explored coinfection-speciﬁc attributes such
as coinfection-associated TB mortality and the possibility of
multiple infection episodes per person for malaria and other
macroparasitic infections.
We examined scenarios exploring 2 assumptions: (1)
the increase in PVL on acquiring a coinfection increases
infectiousness during the period of coinfection, and (2) this
PVL increase additionally reduces individuals’ projected
durations of asymptomatic HIV-1 infection (Fig. 1). We
measured the change in the transmission potential due to this
change in PVL. Transmission events attributable to each
coinfection refer to direct transmission events from a coin-
fected individual (secondary infections).
The relationship between PVL and HIV-1 infectious-
ness estimated by Fraser et al9 shows a plateauing of
FIGURE 1. Schematic diagram illustrating the estimated impact of HIV-1 coinfections that increase HIV-1 PVL on (A) set-point
PVL, (B) duration of asymptomatic HIV-1 infection, (C) HIV-1 transmission rate (hazard of transmission: probability of HIV-1
transmission per year), and (D) HIV-1 transmission potential (product of hazard of transmission and duration of asymptomatic
infection) for 2 hypothetical patients. Time starts at the beginning of each individual’s asymptomatic period (ie, after high PVL
accompanying primary infection). The individual with lower set-point PVL has a correspondingly longer duration of asymptomatic
infection (A). The figure shows that all patients experiencing an increase in PVL as a result of coinfection would experience
decreases in duration of asymptomatic infection and increases in HIV-1 infectiousness, but the direction of change to transmission
potential depends on baseline set-point PVL and the amount that PVL is augmented on coinfection. See Baggaley et al7 for further
explanation. The frequency distribution of set-point PVLs used in the analysis, based on a model fit27 to data from Orange County,
South Africa,16 is shown in gray in (B–D) and shows that HIV-1–infected individuals with set-point PVLs typical of South Africa
could have an increase or decrease in transmission potential as a result of modest decrease in PVL.
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infectiousness at high PVL (Fig. 1C; also see Fig. 3a of Fraser
et al, which demonstrates the plateau for Ugandan2 and
Zambian3 data). We explore the impact of this assumption by
performing the analysis ﬁrst using this plateauing function
and then repeating the analysis using a widely used log-linear
relationship estimated from the same Ugandan2 data: each log
increment in PVL increases infectiousness by a factor 2.45
(see Fig. S2 for comparison of PVL-infectiousness relation-
ships deﬁned by Fraser9 and Quinn2). The model was
programmed and analyzed using Stata version 13.1 (StatCorp
LP, College Station, TX).
RESULTS
Under the assumption that changes in PVL only affect
infectiousness, for every 100 HIV-1–infected people, each
suffering 1 episode of TB, there are 4.9 (0.2–21.5) excess
onward HIV-1 transmission events attributable to TB co-
infection (2.7th–97.5th percentile; Fig. 2). Excess onward
HIV-1 transmissions for other coinfections are 0.4 (0.0–2.0)
for malaria, 3.1 (0.1–14.9) for STH, 8.5 (0.2–38.6) for
schistosomiasis, 13.3 (0.3–89.2) for ﬁlariasis, 0.1 (0.0–1.6)
for syphilis, 4.0 (0.0–24.2) for HSV, and 2.1 (0.1–8.0) for
gonorrhea. These represent coinfections acquired halfway
through the HIV-1 asymptomatic period; coinfections
acquired at the start of asymptomatic HIV-1 resulted in larger
impacts for the longer duration infections only, such as HSV
and ﬁlariasis (data not shown).
Under the assumption that changes in PVL due to
coinfection affect both infectiousness and duration of infec-
tion, the impact of increased PVLs on transmission at the
population is reduced (Fig. 2), with all the conﬁdence
intervals for number of HIV-1 transmissions crossing zero.
In fact, HIV-1 transmission events attributable to coinfection
are negative because the impact of increased infectiousness of
individuals because of elevated PVL is outweighed by the
reduction in survival also conferred by the higher PVL—there
is less opportunity to transmit.
Long-lived infections with relatively large impacts on
PVL, such as ﬁlariasis, conferred the most public health
impact but also the greatest uncertainty in impact [ﬁlariasis:
1.2 (0.4–2.7) life-years lost per episode of coinfection
compared with syphilis: 0.01 (0.00–0.09)]. Averting ﬁlariasis
and schistosomiasis episodes may have a substantial impact
in terms of life-years gained during HIV-1 asymptomatic
infection, thus delaying time until ART is required. However,
most coinfections are accompanied by too small an increase
in PVL to have a substantial impact.
For the shorter lived infections, there is, of course, the
possibility of multiple infections, which would increase their
impact on PVL and transmission. Annual episodes of malaria
infection, representing seasonality among the adult population,
increased impact from 0.4 (0.0–2.0) HIV-1 transmissions
attributable to 100 coinfection episodes to 2.4 (0.0–21.0)
HIV-1 transmissions per 100 people who become infected
with malaria annually over their entire duration of asymptom-
atic HIV-1 infection (results assume PVL change affects
infectiousness but not survival). We did not consider endemic
continuous infection with malaria or STH and schistosomiasis
because endemic infection (ie, constant reinfection) would be
rare among adults in high-intensity settings of sub-Saharan
Africa, the majority of which would be among young children.
Annual acquisition of gonorrhea throughout asymptomatic
HIV-1 infection, representing extremely high-risk individuals,
would lead to 12.1 (0.3–85.3) HIV-1 transmissions attributable
to coinfection over the asymptomatic HIV-1 infection period of
100 people [estimates for syphilis: 0.4 (0.0–13.9) transmis-
sions]. A more realistic level of 3 episodes over the
asymptomatic HIV-1 period produces estimates of 6.2 (0.4–
24.0) for gonorrhea and 0.3 (0.0–4.9) for syphilis.
We investigated the sensitivity of our ﬁndings to
different assumptions regarding the PVL-infectiousness rela-
tionship. Using the PVL-infectiousness function deﬁned by
Quinn et al2 increased the impact of coinfections, predicting
more onward HIV-1 transmission events per episode of
coinfection (see gray plots in Fig. 2). This is because the
Quinn function predicts higher infectiousness than the Fraser
FIGURE 2. Estimated impact of co-
infections on duration of HIV-1
infection and onward HIV-1 trans-
mission. Points represent medians
and error bars represent 2.5th and
97.5th percentiles of output from
10,000 simulated individuals. Cal-
culations assume that each co-
infection is acquired halfway
through the HIV-1 asymptomatic
period. Plot in blue shows results
under the assumption that changes
in PVL only affect HIV-1 infectious-
ness. Plots in green show results
under the assumption that changes
in PVL change duration of infec-
tiousness (middle plot of change in life-years) and infectiousness (right-hand plot). Therefore, there is impact in terms of both
transmission and life-years gained (preceding initiating ART). Change in HIV-1 transmission events plots additionally show results
using the Quinn et al2 PVL-infectiousness relationship (results shown in gray). STH, soil-transmitted helminths (excluding
schistosomiasis).
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function for a given PVL, but this may overestimate
infectiousness (see Figure S2, Supplemental Digital Content,
http://links.lww.com/QAI/A619).
DISCUSSION
For most HIV-1 coinfections, the duration of coinfection
is too short and/or the PVL elevation too modest to reduce
HIV-1 transmission or the duration of asymptomatic HIV-1
infection substantially. However, for longer duration infections
such as HSV and ﬁlariasis, there may be beneﬁt in averting or
treating coinfection to delay time to HIV-1 treatment initiation,
but the impact of coinfections and their treatment depends on
the baseline HIV-1 PVL of the individual.
Scenarios incorporating the impact of TB-associated
mortality during HIV-1 asymptomatic infection were inves-
tigated (methods and results available on request), which
realized the intuitive outcome that life-years saved by
preventing TB infection increased, whereas fewer onward
transmission events were possible because a proportion of
those dually infected would die before transmitting infection.
Multiple episodes of coinfection within the same individual
during asymptomatic HIV-1 infection increase impact. How-
ever, for coinfections where multiple infections are likely,
such as malaria and gonorrhea, the PVL elevations per
episode remain too small to generate a substantial effect,
even when considering annual episodes.
Reductions in HIV-1 PVL can have positive or negative
effects on transmission potential depending on individuals’
baseline PVL and the effect on survival, for which there is
biological plausibility but, as yet, limited empirical evidence.
Mugwanya et al18 recently achieved a .1 log10 copies per
milliliter reduction in HIV-1 PVL among HSV/HIV-1–
coinfected individuals taking high-dose valacyclovir. How-
ever, a signiﬁcant reduction in PVL is insufﬁcient evidence of
beneﬁcial public health impact. Figure 2 suggests that such
a reduction in HIV-1 PVL would reduce the overall onward
HIV-1 transmission of individuals with asymptomatic infec-
tion, in the absence of ART, but the error bars indicate that for
those with higher set-point PVL, a 1 log10 copies per milliliter
reduction would push them to higher transmission potential,
not lower. Therefore, an intervention such as high-dose
valacyclovir in the absence of ART would not be suitable
for targeting to patients with high viremia. Although it may be
cost saving in terms of delaying time at which point ART is
required on clinical grounds, the potential for patients to
transmit HIV-1 to their partners must also be taken into
consideration, with suitable counseling and transmission-
reducing interventions being essential to avoid negative
effects on a longer timescale. Although the prospect of
universal ART as treatment-as-prevention may leave this
issue redundant, the trial results that will prove the success of
this approach at the population level (rather than during
clinical trials19) are not yet in our hands, and with rationing of
scarce resources, the use of lower cost treatments to delay the
time of ART initiation may remain important. Our evaluation
of the inﬂuence of coinfections on onward HIV-1 trans-
mission among individuals not being treated for their HIV-1
infection remains informative because it would be premature
to state that untreated undiagnosed HIV-1 infection is a thing
of the past. For example, Public Health England estimated
that in 2012, 22% of people living with HIV-1 in the United
Kingdom, where there is relatively easy access to testing and
treatment, were unaware of their infection.20 Our analysis
relates to HIV-1 infectiousness during asymptomatic HIV-1
infection, an infection stage at which fewer patients are
treated than during AIDS.
There are a number of limitations to our analysis. For
example, the duration of infection for many of these
infections may be longer for HIV-1–infected than for
uninfected individuals. We could only make predictions for
those coinfections where estimates of increases in PVL on
coinfection are available in published literature. We also
assumed no decrease in sexual activity as a result of
coinfection, which would reduce numbers still further and
therefore support our conclusion of limited impact of most
coinfections on onward HIV-1 transmission events. Evi-
dently, there is beneﬁt to each individual of treating or curing
each coinfection apart from the impact on their HIV-1
infection. Data on the duration of HIV-1 infection are from a
population of Dutch homosexual men,21 whereas data under-
lying HIV-1 infectiousness assumptions are from Ugandan2
and Zambian3 populations. However, Fraser et al show a direct
side-by-side comparison of survival rates between the Dutch
seroconverters data set and a cohort of untreated female sex
workers from Nairobi, Kenya, followed since seroconversion,22
which show very similar survival rates for individuals in
similar PVL classes (see Figure S6, Supplemental Digital
Content, http://links.lww.com/QAI/A619).9 Our assumption
that changes in PVL affect survival is tentative, and we
know that survival and rates of CD4 decline are affected by
factors other than changes in PVL. For example, in Rakai,
Uganda, subtypes A and D have very different survival
proﬁles despite similar PVLs.23 Our analysis therefore
presents outcomes with and without the assumption that
changing PVL can alter HIV-1 disease progression. Our
modeling framework does not use a population-level
epidemic model of ongoing HIV-1 transmission; further
investigation of the effect of coinfections on the time course
of HIV-1 epidemics could be devised using dynamical
epidemic models.
We have focussed on the long incubation period of
HIV-1 infection, during which the PVL-infectiousness rela-
tionship holds.2,9 The effect of coinfection during symptom-
atic (late-stage) HIV-1 will likely be less, as individuals
become less sexually active with disease progression. Co-
infection during the high viremia accompanying acute
infection may increase infectiousness even further, but we
postulate the additional impact due to coinfections is small.
The Fraser et al9 PVL-infectiousness model provides strong
evidence of saturation of infectiousness at high PVLs (Fig. S2
and Fig. 3 of Fraser et al), so a half log augmentation due to
coinfection would not markedly affect transmission. During
acute infection, the PVL-infectiousness relationship is less
clear: transmission rates have been shown to be signiﬁcantly
higher than would be expected on the basis of PVL (see Fig. 3
of Hollingsworth et al15). Authors postulate that sexually
transmitted infection (STI) coinfections may in part be
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responsible for this, but this may be through mechanisms
other than PVL (eg, portals of access for ulcerative STIs), and
acute HIV-1 virus phenotype may be more transmissible than
that which evolves during incubation.
Our analysis focuses on the relationship between PVL and
HIV-1 transmission, but an association between genital viral
shedding and transmission has also been observed, independent
of PVL.24 This relationship is less studied than that for PVL and
is less reliable (Baeten et al found that, of 78 transmission events
in their study, 11 occurred from persons with undetectable
genital HIV-1 RNA despite detection of PVL24). Nonetheless, it
is levels of virus in the genital tract at the point of sex which
determine likelihood of transmission, and these levels are likely
to rise above that observed for PVL in the case of STI, due to
local genital inﬂammation. This may increase the effect of the
STIs included in this analysis beyond the effect predicted here
through PVL evaluation; ulcerative STIs such as HSV and
syphilis will further increase risk. However, the Rakai and
Zambia studies show that PVL is the dominant predictor of
transmission between discordant couples, and so it is currently
the most suitable tool for measuring these effects.
Several research groups have recently suggested that
increased PVLs, due in part to coinfection, are responsible for
the large HIV-1 epidemics in sub-Saharan Africa.1,25 Our results
suggest that some coinfections play a signiﬁcant role, but it must
be noted that although many of these coinfections are very
prevalent in regions with high HIV-1 prevalence, they are not
necessarily affecting those individuals who play a substantial
role in HIV-1 transmission. For example, non-hookworm STH
such as Ascaris lumbricoides predominantly affect children.26
The association between HIV and these coinfections has been
investigated by a number of authors, but data are rarely routinely
collected in a way which would enable a population-speciﬁc
estimate of the impact of these coinfections on viral load.
Our ﬁndings change markedly with the assumptions
we make regarding the impact of changes in PVL on
survival. The results presented here highlight the importance
of understanding the relationship between PVL and duration
of infection to estimate the population impact of any
coinfection or intervention, which alters the PVL of HIV-
1–infected individuals.
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